Potential Next-Generation Prostate Cancer Therapy Found

News The potential foundation for a next-generation therapy, called tetraaryl cyclobutane, or CB, is being studied as an option for prostate tumors that have grown resistant to current anti-androgen drugs, notably enzalutamide. Contributed Author:  Duke University Medical Center Topics:  Oncology